Pharmacokinetics of mycophenolic acid and metabolites in diabetic kidney transplant recipients

Therapeutic Drug Monitoring

Volumn 28, Issue 1, 2006, Pages 95-101

  Akhlaghi, Fatemeh ^a,c   Patel, Chirag G ^a   Zuniga, X Patricia ^b   Halilovic, Jenana ^a   Preis, Ido S ^b   Gohh, Reginald Y ^b  

^a UNIVERSITY OF RHODE ISLAND   (United States)

^b BROWN UNIVERSITY   (United States)

^c UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

Acetaminophen; Acyl MPAG; Diabetes; Mycophenolic acid; Pharmacokinetics

Indexed keywords

BENZENE DERIVATIVE; CYCLOSPORIN; DRUG METABOLITE; GLUCURONIDE; IOHEXOL; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PARACETAMOL; PREDNISONE; TACROLIMUS; ANALGESIC AGENT; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG ABSORPTION; DRUG BLOOD LEVEL; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; MALE; PRIORITY JOURNAL; STEADY STATE; STOMACH EMPTYING; BLOOD; CLINICAL TRIAL; DRUG EFFECT; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY TRANSPLANTATION; METABOLISM; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS;

ACETAMINOPHEN; ADULT; ANALGESICS, NON-NARCOTIC; AREA UNDER CURVE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; GASTRIC EMPTYING; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID;

EID: 33745491120     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ftd.0000189898.23931.3f     Document Type: Article

References (27)

1. Sollinger HW for the U.S. renal transplant mycophenolate mofetil study group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation. 1995;60:225-232.
2. Bullingham R, Monroe S, Nicholls A, et al. pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. J Clin Pharmacol. 1996;36:315-324.
3. Nowak I, Shaw LM. Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics. Clin Chem. 1995;41:1011-1017.
4. Shipkova M, Armstrong VW, Oellerich M, et al. Acyl glucuronide drug metabolites: toxicological and analytical implications. Ther Drug Monit. 2003;25:1-16.
5. Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet. 1998;34:429-455.
6. Wynn JJ, Distant DA, Pirsch JD, et al. Kidney and pancreas transplantation. Am J Transplant. 2004;4(Suppl 9):72-80.
7. Kasiske BL, Snyder JJ, Gilbertson D, et al. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant. 2003;3:178-185.
8. Gwilt PR, Nahhas RR, Tracewell WG. The effects of diabetes mellitus on pharmacokinetics and pharmacodynamics in humans. Clin Pharmacokinet. 1991;20:477-490.
9. Watkins JB III, Sherman SE. Long-term diabetes alters the hepatobiliary clearance of acetaminophen, bilirubin and digoxin. J Pharmacol Exp Ther. 1992;260:1337-1343.
10. Zini R, Riant P, Barre J, et al. Disease-induced variations in plasma protein levels, implications for drug dosage regimens (part I). Clin Pharmacokinet. 1990;19:147-159.
11. Zanker B, Sohr B, Eder M, et al. Comparison of MPA trough levels in patients with severe diabetes mellitus and from non-diabetics after transplantation. Transplant Proc. 1999;31:1167.
12. Pescovitz MD, Guasch A, Gaston R, et al. Equivalent pharmacokinetics of mycophenolate mofetil in African-American and Caucasian male and female stable renal allograft recipients. Am J Transplant. 2003;3:1581-1586.
13. van Hest RM, Mathot RA, Vulto AG, et al. Mycophenolic acid in diabetic renal transplant recipients: pharmacokinetics and application of a limited sampling strategy. Ther Drug Monit. 2004;26:620-625.
14. Soman RS, Zahir H, Akhlaghi F. Development and validation of an HPLC-UV method for determination of iohexol in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2005;816:339-343.
15. Willems M, Quartero AO, Numans ME. How useful is paracetamol absorption as a marker of gastric emptying? A systematic literature study. Dig Dis Sci. 2001;46:2256-2262.
16. Patel CG, Mendonza AE, Akhlaghi F, et al. Determination of total mycophenolic acid and its glucuronide metabolite using liquid chromatography with ultraviolet detection and unbound mycophenolic acid using tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;813:287-294.
17. Center for Drug Evaluation and Research. (FDA), Guidance for Industry: Bioanalytical Method Validation, 2001. Available at: http://www.fda.gov/cder/ guidance/4252fnl.htm. Date accessed November 2005.
18. Brunner LJ, Bai S. Simple and rapid assay for acetaminophen and conjugated metabolites in low-volume serum samples. J Chromatogr B Biomed Sci Appl. 1999;732:323-329.
19. Rowland M, Tozer TN. Clinical Pharmacokinetics, Concepts and Applications. 3rd ed. Philadelphia: Williams & Wilkins; 1995.
20. Kelly K, O'Mahony B, Lindsay B, et al. Comparison of the rates of disintegration, gastric emptying, and drug absorption following administration of a new and a conventional paracetamol formulation, using gamma scintigraphy. Pharm Res. 2003;20:1668-1673.
21. Kaplan B, Gruber SA, Nallamathou R, et al. Decreased protein binding of mycophenolic acid associated with leukopenia in a pancreas transplant recipient with renal failure. Transplantation. 1998;65:1127-1129.
22. Zini R, Riant P, Barre J, et al. Disease-induced variations in plasma protein levels, implications for drug dosage regimens (part II). Clin Pharmacokinet. 1990;19:218-229.
23. Okabe N, Hashizume N. Drug binding properties of glycosylated human serum albumin as measured by fluorescence and circular dichroism. Biol Pharm Bull. 1994;17:16-21.
24. Picard N, Ratanasavanh D, Premaud A, et al. Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos. 2005;33:139-146.
25. Braun L, Coffey MJ, Puskas F, et al. Molecular basis of bilirubin UDP-glucuronosyltransferase induction in spontaneously diabetic rats, acetone-treated rats and starved rats. Biochem J. 1998;336:587-592.
26. Kobayashi M, Saitoh H, Kobayashi M, et al. Cyclosporin A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by Mrp2 in rats. J Pharmacol Exp Ther. 2004;309:1029-1035.
27. Shaw LM, Korecka M, Venkataramanan R, et al. Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies. Am J Transplant. 2003;3:534-542.